As of June 14, 2025, Heat Biologics Inc (HTBX) reports a EV/EBITDA of -1.50.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Heat Biologics Inc's EV/EBITDA to Peers
To better understand Heat Biologics Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Heat Biologics Inc (HTBX) | -1.50 |
| Aptorum Group Ltd (APM) | 34.55 |
| Abbvie Inc (ABBV) | 18.46 |
| Amgen Inc (AMGN) | 15.50 |
| Regeneron Pharmaceuticals Inc (REGN) | 12.86 |
| Gilead Sciences Inc (GILD) | 9.61 |
Compared to its competitors, Heat Biologics Inc's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.